[{"id":"c3f67f74-ef3d-40b9-bda8-c2b58e4682ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04836195","created_at":"2021-04-08T13:52:40.387Z","updated_at":"2024-07-02T16:35:11.754Z","phase":"Phase 1","brief_title":"Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma","source_id_and_acronym":"NCT04836195","lead_sponsor":"Pacylex Pharmaceuticals","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zelenirstat (PCLX-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 10/28/2024","primary_completion_date":" 10/28/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-03"}]